Description

Global Pharmacogenomics Market: by Technology (Polymerase Chain Reaction, Microarray, Sequencing, Electrophoresis, and Others), by Application (Neurology, Oncology, Infectious Diseases, Pain Management, and Others), by End-User (Hospitals & Clinics, Academic Institutes, Research Institutes, and Others) and by Region – Global Industry Sizing, Growth, Trend, Opportunity, and Forecast (2021–2027)

The pharmacogenomics market report covers a thorough analysis of the market dynamics, business models, segmental/regional analysis, and respective market shares and strategies adopted by the key market players operating globally. It entails an in-depth analysis of the factors influencing the global market and market statistics indicating region-wise and segment-wise market share/growth analysis. The report's study will outlook one of the most exhaustive market analyses, capturing all the pharmacogenomics industry aspects.

Pharmacogenomics Industry Outlook

The pharmacogenomics market size was valued at USD 6.53 billion in 2020, which is expected to reach USD 9.47 billion by 2027, registering a CAGR of 7.2% during the forecast period (2021-2027). Pharmacogenomics is the study of pharmacology and genomics in human genes that affect a person’s reaction to a particular drug. Pharmacogenomics aims to ensure effective and safe medications with minimal side effects. Cardiovascular diseases, AIDS, Alzheimer's disease, and cancer are diseases that can be treated by pharmacogenomics.

Factors Affecting the Pharmacogenomics Industry over the Forecast Period:

The rise in the geriatric population, increase in the awareness among patients towards personalized therapy, growing adoption of pharmacogenomics procedures by healthcare professionals, and high prevalence of chronic diseases across the globe are the key factors expected to propel the market growth of the pharmacogenomics market over the forecast period.

Governments also provide financial aids, take initiatives, craft rules & regulations and work towards the development & promotion of pharmacogenomics which affects the market dynamics of pharmacogenomics.

However, the lack of skilled and highly trained healthcare professionals and the high cost associated with the test may restrain the growth of the pharmacogenomics market.

Impact of COVID-19 on Pharmacogenomics Market:

COVID-19 is a global public health disease that has affected almost every industry. The outbreak of COVID-19 increased the demand for pharmacogenomics. This creates many opportunities for new and small-scale players to mark their presence in the regional market and offer low-cost prices and high-quality products to the end-users. Therefore, with the outbreak of the COVID-19, there is a significant surge in demand for pharmacogenomics that has been seen across the globe, which has positively impacted the pharmacogenomics market value in 2020 and subsequent years.

Scope of the Report

The report outlines the global pharmacogenomics market study based on technology, application, and end user.

The pharmacogenomics market has been segmented based on technology –

• Polymerase Chain Reaction
• Microarray
• Sequencing
• Electrophoresis
• Others

The pharmacogenomics market has been segmented based on application –

• Neurology
• Oncology
• Infectious Diseases
• Pain Management
• Others

The pharmacogenomics market has been segmented on the basis of the end user –

• Hospitals & Clinics
• Academic Institutes
• Research Institutes
• Others

Pharmacogenomics Market: Regional Outlook

Based on the region, the global pharmacogenomics market has been segmented into five geographical regions, namely, North America, Asia Pacific, Europe, South America, and the Middle East, and Africa. In 2019, North America held the largest share in the pharmacogenomics market, followed by the Asia Pacific and Europe due to the rising demand for personalized medicine and technological advancement in the region. Moreover, Asia Pacific is expected to project the highest CAGR globally over the forecast periods due to the rapidly increasing aging population and growing R&D centers.

Key Global Pharmacogenomics Market Competitors Includes –

The pharmacogenomics market is highly fragmented, with a large number of small players across the globe. The vital pharmacogenomics market manufacturers operating in the global market are –

• Abbott Laboratories
• Bayer AG
• Dickinson and Company
• Empire Genomics
• F. Hoffmann-La Roche Ltd.
• Illumina Inc.
• Johnson and Johnson Services Inc.
• Merck & Co., Inc.
• Myriad Genetics Inc.
• Opko Health Inc.
• Teva Pharmaceuticals Industries
• Thermo Fisher Scientific Inc.

The pharmacogenomics tools market report provides a thorough analysis of macro-economic factors and every segment's market attractiveness. The report will include an in-depth qualitative and quantitative assessment of the segmental/regional outlook with the market players' presence in the respective segment and region/country. The information concluded in the report includes the inputs.

Pharmacogenomics Market Report Covers Comprehensive Analysis On:

• Market Segmentation & Regional Analysis
• Market Size of 10 years
• Pricing Analysis
• Supply & Demand Analysis
• Product Life Cycle Analysis
• Porter's Five Forces & Value Chain Analysis
• Developed & Emerging Economies Analysis
• PEST Analysis
• Market and Forecast Factor Analysis
• Market Opportunities, Risks, & Trends
• Conclusion & Recommendation
• Regulatory Landscape
• Patent Analysis
• Competition Landscape
• 15+ Company Profiles

Pharmacogenomics Market Regional Analysis Includes:

• North America (US, Canada, Mexico)
• South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
• Europe (Germany, Italy, France, UK, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, the Netherlands, Norway, Sweden, Denmark, Rest of Europe)
• Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, the Philippines, Singapore, Australia & New Zealand, Rest of Asia Pacific)
• The Middle East & Africa (Saudi Arabia, UAE, South Africa, Northern Africa, Rest of MEA

Pharmacogenomics Market: Target Audience

• Investors and trade experts
• Large, medium, and small-sized enterprises
• Venture capitalist
• Healthcare manufacturers, distributors, and suppliers
• Trade publications and magazines
• Government authorities, associations, and organizations

Key Issues Addressed

• What is the market size by various segmentation of the pharmacogenomics by region and its respective countries?
• What are the customer buying behavior, key takeaways, and Porter's 5 forces of the pharmacogenomics market?
• What are the key opportunities and trends for manufacturers involved in the pharmacogenomics supply chain?
• What are the fundamental dynamics (drivers, restraints, opportunities, and challenges) of the market?
• What and how regulations, schemes, patents, and policies are impacting the growth of the market?
• What are the upcoming technological solutions influencing market trends? How will existing companies adapt to the new change in technology?
• What will be the impact of cutting-edge technology on the pharmacogenomics market?
• How has COVID-19 impacted the demand and sales of pharmacogenomics in the global market? Also, the expected BPS drop or rise count of the market and market expected recovery period.
• Detailed analysis of the competitors and their latest launch, and what are the prominent startups introduced in the target market? Also, detailed company profiling of 25+ leading and prominent companies in the market.